- Home
- MLCO vs OCS Comparison
MLCO vs OCS Comparison
Compare MLCO & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MLCO | OCS |
|---|---|---|
| Founded | 2003 | 2003 |
| Country | Hong Kong | Switzerland |
| Employees | N/A | 60 |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.8B |
| IPO Year | 2006 | N/A |
Fundamental Metrics
Financial Performance| Metric | MLCO | OCS |
|---|---|---|
| Price | $5.89 | $11.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $10.10 | ★ $42.00 |
| AVG Volume (30 Days) | ★ 2.1M | 991.8K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.42 | $466.06 |
| Revenue Next Year | $4.37 | $479.73 |
| P/E Ratio | $12.16 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.19 | $11.31 |
| 52 Week High | $10.15 | $34.48 |
Technical Indicators
Market Signals| Indicator | MLCO | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 62.07 | 21.55 |
| Support Level | $5.44 | N/A |
| Resistance Level | $6.07 | $21.00 |
| Average True Range (ATR) | 0.16 | 2.26 |
| MACD | 0.05 | -2.18 |
| Stochastic Oscillator | 79.31 | 1.80 |
Price Performance
Historical ComparisonAbout MLCO Melco Resorts & Entertainment Limited
Melco Resorts & Entertainment is one of only six licensed casino operators in Macao. It operates Altira, a complex focused on premium customers; City of Dreams, an integrated resort in Cotai serving both mass-market and premium patrons; and Mocha Clubs' electronic gaming machines. The company also has a majority interest in Studio City, which opened in 2015. Outside Macao, Melco owns City of Dreams Manila in the Philippines and City of Dreams Mediterranean in Cyprus. The business mix in terms of adjusted EBITDA was about 84% from Macao, with the rest from overseas as of 2025.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.